PTGX Protagonist Therapeutics (PTGX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001377121
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
204
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $8.5M priced
What the filings say about PTGX
Insiders, 180 days
-$57.8M net sold
4 sellers · 33% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$41.8M
2 notices
Protagonist Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Protagonist Therapeutics, Inc insiders sold a net $57.8M of stock across 78 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Apr 20, 2026.
- The trade is 12.0% of the 105,037 shares held after it.
- 1 other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Ali Asif sold about $1.8M of PTGX under a 10b5-1 plan on Sep 30, 2026; 1 other insider sold within 30 days and 204 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Apr 20, 2026.
- The trade is 78.0% of the 59,003 shares held after it.
- 1 other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Ali Asif sold about $6.5M of PTGX under a 10b5-1 plan on Sep 30, 2026; 1 other insider sold within 30 days and 204 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Sep 9, 2026.
- The trade is 1.4% of the 522,968 shares held after it.
- 1 other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO PATEL DINESH V PH D sold about $1.0M of PTGX under a 10b5-1 plan on Sep 10, 2026; 1 other insider sold within 30 days and 204 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 8, 2026.
- The trade is 12.2% of the 522,968 shares held after it.
- 1 other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO PATEL DINESH V PH D sold about $9.3M of PTGX under a 10b5-1 plan on Sep 9, 2026; 1 other insider sold within 30 days and 204 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Aug 11, 2026.
- The trade is 10.4% of the 522,968 shares held after it.
- 1 other insider sold within 30 days.
- 204 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO PATEL DINESH V PH D sold about $7.9M of PTGX under a 10b5-1 plan on Sep 8, 2026; 1 other insider sold within 30 days and 204 funds added in the latest 13F quarter.78 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$57.8M over 180 days
-$41.4M over 90 days
below 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
204 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
-89.4% year over year
below 89% of Pharma & Biotech
Margin
-282.8% net margin
below 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.7% of the float short (float per yahoo 2026-10-26) · 11.5 days to cover · settled 2026-09-30
more than 83% of Pharma & Biotech
What changed in the last 30 days
Oct 2Chief Financial Officer Ali Asif sold $8.3M under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer ASIF ALI filed to sell $8.3M by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch PTGX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+89.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PTGX: institutional holders (13F)
13F holdings, latest reported quarter
10,307,837 sh
$1.3B
6,348,906 sh
$778.2M
5,061,175 sh
$620.4M
3,629,298 sh
$444.9M
3,416,781 sh
$418.8M
Congress trades in PTGX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PTGX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ASIF ALI
Filed 2026-09-30
$8.3M
Dinesh Patel
Filed 2026-08-10
$33.6M
WILLIAM WADDILL
Filed 2026-06-23
$1.0M
PTGX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$9.6M position · as of 2026-07-31
3.4%
Invesco S&P SmallCap Health Care ETF
$4.1M position · as of 2026-05-31
3.1%
Neuberger Disrupters ETF
$1.1M position · as of 2026-05-31
3.0%
Invesco S&P SmallCap Momentum ETF
$77.9M position · as of 2026-07-31
2.6%
AlphaCentric Life Sciences and Healthcare Fund
$1.1M position · as of 2026-06-30
2.4%
SBH SMALL CAP GROWTH FUND
$6.1M position · as of 2026-06-30
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
5
Phase 2
0 active
2
Phase 3
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Patel
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.1M
$15.3M
$1.8M
+14%
n/a
2022
$6.0M
-$5.2M
$2.5M
-46%
n/a
2021
$5.5M
$12.1M
$2.2M
+70%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $57.8M sold by insiders over 180 days, 204 funds added last quarter, $41.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PTGX financials
Revenue growth
-89.4%
XBRL, annual
Net margin
-282.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$282.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PTGX
| FY Dec 2025 | $46.0M |
| FY Dec 2024 | $434.4M |
| FY Dec 2023 | $60.0M |
| FY Dec 2022 | $26.6M |
| FY Dec 2021 | $27.4M |
| Jun 2026 | $213.5M |
| Mar 2026 | $56.4M |
| Dec 2025 | $7.4M |
| Sep 2025 | $4.7M |
| Jun 2025 | $5.5M |
| Mar 2025 | $28.3M |
| Dec 2024 | $170.6M |
| Sep 2024 | $4.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+29.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PTGX
| FY Dec 2025 | -282.8% |
| FY Dec 2024 | +63.3% |
| FY Dec 2023 | -131.6% |
| FY Dec 2022 | -479.3% |
| FY Dec 2021 | -458.9% |
| Jun 2026 | +76.3% |
| Mar 2026 | +6.7% |
| Dec 2025 | -596.8% |
| Sep 2025 | -834.9% |
| Jun 2025 | -627.0% |
| Mar 2025 | -41.2% |
| Dec 2024 | +77.2% |
| Sep 2024 | -710.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$130.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PTGX
| FY Dec 2025 | $56.1M |
| FY Dec 2024 | $182.8M |
| FY Dec 2023 | -$70.8M |
| FY Dec 2022 | -$108.9M |
| FY Dec 2021 | -$109.0M |
| Jun 2026 | $218.9M |
| Mar 2026 | -$49.2M |
| Dec 2025 | -$37.1M |
| Sep 2025 | -$2.0M |
| Jun 2025 | -$29.6M |
| Mar 2025 | $124.8M |
| Dec 2024 | -$29.5M |
| Sep 2024 | -$28.6M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term debt only, 2020-03-31 (76 months older than the period end); equity 2026-06-30
Debt to equity PTGX
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
13.34x
TTM operating cash flow over long-term debt only, 2020-03-31 (76 months older than the period end)
Cash flow to debt PTGX
| FY Dec 2025 | 5.87x |
| FY Dec 2024 | 18.73x |
| FY Dec 2023 | -7.14x |
| FY Dec 2022 | -11.00x |
| FY Dec 2021 | -10.97x |
| Jun 2026 | 13.34x |
| Mar 2026 | -11.86x |
| Dec 2025 | 5.87x |
| Sep 2025 | 6.66x |
| Jun 2025 | 4.02x |
| Mar 2025 | 34.27x |
| Dec 2024 | 18.73x |
| Sep 2024 | 23.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+11.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PTGX
| FY Dec 2025 | -20.2% |
| FY Dec 2024 | +54.4% |
| FY Dec 2023 | -28.6% |
| FY Dec 2022 | -49.4% |
| FY Dec 2021 | -43.3% |
| Jun 2026 | +11.0% |
| Mar 2026 | -17.1% |
| Dec 2025 | -20.2% |
| Sep 2025 | +7.8% |
| Jun 2025 | +8.6% |
| Mar 2025 | +9.0% |
| Dec 2024 | +54.4% |
| Sep 2024 | +41.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PTGX
| FY Dec 2025 | -18.4% |
| FY Dec 2024 | +49.9% |
| FY Dec 2023 | -26.1% |
| FY Dec 2022 | -42.8% |
| FY Dec 2021 | -37.4% |
| Jun 2026 | +10.3% |
| Mar 2026 | -15.9% |
| Dec 2025 | -18.4% |
| Sep 2025 | +7.0% |
| Jun 2025 | +7.8% |
| Mar 2025 | +8.2% |
| Dec 2024 | +49.9% |
| Sep 2024 | +36.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+12.2%
operating income after a 1.7% effective tax rate, over long-term debt only, 2020-03-31 (76 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PTGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | +66.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +12.2% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +3.8% |
| Jun 2025 | +6.6% |
| Mar 2025 | +5.6% |
| Dec 2024 | +66.6% |
| Sep 2024 | +59.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PTGX
| FY Dec 2025 | -24.0% |
| FY Dec 2024 | +48.9% |
| FY Dec 2023 | -33.8% |
| FY Dec 2022 | -50.5% |
| FY Dec 2021 | -42.8% |
| Jun 2026 | +7.6% |
| Mar 2026 | -20.8% |
| Dec 2025 | -24.0% |
| Sep 2025 | +3.1% |
| Jun 2025 | +3.8% |
| Mar 2025 | +4.2% |
| Dec 2024 | +48.9% |
| Sep 2024 | +34.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
137.57x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PTGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | 9.13x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 120.18x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 102.20x |
| Jun 2025 | 75.71x |
| Mar 2025 | 62.00x |
| Dec 2024 | 9.13x |
| Sep 2024 | 16.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.7B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2020-03-31 (76 months older than the period end), minus cash 2026-06-30
Enterprise value PTGX
| FY Dec 2025 | $5.3B |
| FY Dec 2024 | $2.2B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $420.8M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $7.5B |
| Mar 2026 | $6.5B |
| Dec 2025 | $5.3B |
| Sep 2025 | $4.0B |
| Jun 2025 | $3.3B |
| Mar 2025 | $2.8B |
| Dec 2024 | $2.2B |
| Sep 2024 | $2.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield PTGX
| FY Dec 2025 | +1.0% |
| FY Dec 2024 | +7.9% |
| FY Dec 2023 | -5.4% |
| FY Dec 2022 | -20.3% |
| FY Dec 2021 | -6.7% |
| Jun 2026 | +1.7% |
| Mar 2026 | -1.8% |
| Dec 2025 | +1.0% |
| Sep 2025 | +1.5% |
| Jun 2025 | +1.1% |
| Mar 2025 | +11.3% |
| Dec 2024 | +7.9% |
| Sep 2024 | +8.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
3.46x
P/E over trailing EPS growth of 40%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PTGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 3.03x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M |
| Net income | -$130.1M | $275.2M | -$79.0M | -$127.4M |
| EPS (diluted) | -2.05 | 4.23 | -1.39 | -2.60 |
| Operating cash flow | $57.7M | $184.2M | -$70.2M | -$108.1M |
| Cash | $128.4M | $97.2M | $186.7M | $125.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
PTGX Stock Sonar score 6/7 axes
Find similar shapesComparePTGX ranks highest on institutional and government (90th percentile) and financial health (87th), and lowest on insider conviction (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PTGX filings, in plain words
Are Protagonist Therapeutics insiders buying or selling PTGX?
In the 180 days to 2026-10-28, Protagonist Therapeutics insiders were net sellers, a net $57.8M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of PTGX?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $41.8M of stock; the latest, by ASIF ALI, was filed 2026-09-30.
Read the full summary
In the 180 days to 2026-10-28, Protagonist Therapeutics insiders were net sellers of PTGX, a net $57.8M across purchases and sales reported on Form 4 by 4 sellers. 33% of the 15 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $41.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
